TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00678067

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Description: Soft capsules 500 mg/each; 1 capsule/day for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)
Description: Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Germ oil
Description: Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
Study: NCT03618368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA-500 dialyzer
Description: THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
Study: NCT03901170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
Study: NCT00937352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bapineuzumab
Description: 0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bapineuzumab
Description: 0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.
Study: NCT03070288

Intervention type: OTHER
Intervention: Red-green-blue measurements of nasal mucosa image
Description: Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area

Intervention type: OTHER
Intervention: Red-green-blue measurements of nasal mucosa image
Description: Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
Study: NCT01517750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICON Auto CPAP™ with Thermosmart heated tube
Description: ICON Auto CPAP™ with heated humidification and the use of a heated tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICON Auto CPAP™ without Thermosmart heated tube
Description: ICON Auto CPAP™ without heated humidification or the use of a heated tube.
Study: NCT01298479

Intervention type: OTHER
Intervention: Uniject
Description: single use container
Study: NCT02534376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe 10mg-simvastatin 40mg
Description: Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
Study: NCT01716286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low fat vs. essence yoghurt
Study: NCT02099240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral antibiotics
Description: intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous antibiotics
Description: intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
Study: NCT00678067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: National Cholesterol Education Program (NCEP) Step I Diet
Description: Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: National Cholesterol Education Program (NCEP) Step I Diet
Description: Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: National Cholesterol Education Program (NCEP) Step I Diet
Description: Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
Study: NCT01141725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study: NCT02717247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tRNS
Description: The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tRNS
Description: The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
Study: NCT04725084

Intervention type: OTHER
Intervention: Use of High Flow Nasal Cannula alone
Description: Use of high flow nasal cannula oxygen therapy alone

Intervention type: OTHER
Intervention: Use of Non-invasive Ventilation
Description: Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy

Intervention type: OTHER
Intervention: Use of Continuous Positive Airway Pressure
Description: Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
Study: NCT00028665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab IV over 2-5 hours on days 1, 8, and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Description: After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
Study: NCT03618368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA-500 dialyzer
Description: THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: REVACLEAR-400 dialyzer
Description: REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: REVACLEAR-400 dialyzer
Description: REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
Study: NCT00307502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: tablets 200 mg, 400 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: tablets 600 mg, 600 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir
Description: Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: tablets 250 mg, 2500 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir
Description: Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: capsules 200 mg, 400 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Description: Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fos-amprenavir/ritonavir
Description: Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study: NCT02257593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein
Study: NCT04123886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
Study: NCT01391364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SofLens in investigational solution
Description: SofLens in investigational solution, worn on a daily disposable basis for 7 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SofLens in currently marketed solution
Description: SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
Study: NCT00668421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701 (Lestaurtinib)
Description: Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
Study: NCT02122835

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic exercise training
Description: 12 weeks of supervised aerobic exercise training

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic exercise training
Description: 12 weeks of supervised aerobic exercise training
Study: NCT02249806

Intervention type: OTHER
Intervention: PH target therapy according to physician
Description: Patients receiving PH target therapy
Study: NCT01777035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early PT OT
Description: 1. Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.~2. active assisted ROM in supine position.~3. treatment is advanced to bed mobility activities~4. sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. progression to transfer training, and finally pre-gait training and ambulation.~6. progression of activities dependent on patient tolerance and stability~7. therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged.
Study: NCT00828243

Intervention type: DRUG
Intervention: Nutrient
Description: We administer stable isotopically labeled precursors of surfactant phospholipids (\[1-13C1\] acetate) and of surfactant protein-B (\[5,5,5-2H3\] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
Study: NCT05490017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
Study: NCT02137863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography.
Study: NCT00307502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir/ ritonavir
Description: Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day
Study: NCT02137863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % NaCl
Description: During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9 % NaCl
Description: During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % NaCl
Description: 100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure
Study: NCT00282035

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI utilizing 3D-CRT radiation
Description: Accelerated partial breast irradiation utilizing 3D-CRT

Intervention type: RADIATION
Group type: OTHER
Intervention: Whole breast irradiation
Description: Whole breast irradiation
Study: NCT03921749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting.
Study: NCT03758781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX 2
Description: IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
Study: NCT04924062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to pembrolizumab
Study: NCT01810770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
Study: NCT00308139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide, long acting release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Study: NCT03253393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Touch Technology packaging
Description: hioxifilcon A contact lens in Smart Touch Technology (hydrogel, no EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, with EDTA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Touch Technology packaging
Description: hioxifilcon A contact lens in Smart Touch Technology (hydrogel, no EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, with EDTA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional lens packaging
Description: hioxifilcon A contact lens in conventional lens packaging (hydrogel, no EDTA) midafilcon A contact lens in conventional lens packaging (silicone hydrogel, with EDTA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional lens packaging
Description: hioxifilcon A contact lens in conventional lens packaging (hydrogel, no EDTA) midafilcon A contact lens in conventional lens packaging (silicone hydrogel, with EDTA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDTA
Description: hioxifilcon A contact lens in Smart Touch Technology (hydrogel, with EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, no EDTA)
Study: NCT01889823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: Subjects will be breathing 100% oxygen
Study: NCT01005251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesogaberan (AZD3355)
Description: 60 mg, oral, capsules, bid for 4 w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesogaberan (AZD3355)
Description: 120 mg, oral, capsules, bid for 4 w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesogaberan (AZD3355)
Description: 180 mg, oral, capsules, bid for 4 w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesogaberan (AZD3355)
Description: 240 mg, oral, capsules, bid for 4 w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral,capsules, bid for 4 w
Study: NCT03446755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra uterine Cook balloon
Description: Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
Study: NCT03752138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: TK216
Description: Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: TK216
Description: Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Decitabine 10mg/m2
Description: 10mg/m2 by vein on Days 1-10 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Decitabine 20 mg/m2
Description: 20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expansion Phase TK216
Description: Expansion cohort will receive the RP2D of TK216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expansion Phase Decitabine
Description: Expansion cohort will receive the RP2D of Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: TK216
Description: Recommended dose from Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: TK216
Description: Recommended dose from Part 1.
Study: NCT03092583

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: 35 mL, 7 tubes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 35 mL, 7 tubes
Study: NCT02660788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Reminder Postcard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Reminder Postcard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Physician Reminder Letter